{
    "nct_id": "NCT05271409",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab As Monotherapy Or In Addition To Baseline Therapy In Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)",
    "inclusion_criteria": "Inclusion criteria\n\n* Participants who are aged >=12 years at the time of signing Informed Consent Form\n* Confirmed diagnosis of MOGAD with a history of >=1 MOGAD relapse in the 12 months prior to screening or >=2 attacks in the 24 months prior to screening\n* Expanded Disability Status Scale (EDSS) score of 0-6.5 at screening\n* Best corrected visual acuity (HCVA) better than 20/800 in each eye at screening\n* Participants receiving either no or ongoing chronic immunosuppressant treatment (IST) for MOGAD at the time of screening\n* For women of childbearing potential: participants who agree to remain abstinent or use adequate contraception during the treatment period and for at least 3 months after the final dose of satralizumab\n\nExclusion criteria\n\n* Presence of aquaporin-4-antibodies (AQP4-IgG) in the serum\n* History of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis\n* Any concomitant disease other than MOGAD that may require treatment with ISTs or OCS or intravenous (IV) corticosteroids at doses >20 mg prednisone equivalent per day for >21 days during the study\n* Participants who are pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of satralizumab\n* Participants with active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline\n* Participants with evidence of latent or active tuberculosis (excluding patients receiving chemoprophylaxis for latent tuberculosis infection)\n* Participants with positive screening tests for hepatitis B and C\n* Receipt of live or live attenuated vaccine within 6 weeks prior to baseline\n* History of severe allergic reaction to a biologic agent\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}